

IARC Monographs on the Identification of Carcinogenic Hazards to Humans

Volume 140: Atrazine, Alachlor, and Vinclozolin

Lyon, France: 28 October to 4 November 2025

LIST OF PARTICIPANTS

Working Group Members served in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Members

Sunny Abarikwu, University of Port Harcourt, Nigeria

Isabelle Baldi, Bordeaux Population Health centre and Institut national de la santé et de la recherche médicale (INSERM), France

Dana Barr, Emory University, USA

Laura Beane Freeman, Occupational and Environmental Epidemiology Branch, United States National Cancer Institute, USA (unable to attend)

Sylvie Bortoli, Université Paris Cité and Institut national de la santé et de la recherche médicale (INSERM), France

Russell Cattley, College of Veterinary Medicine, Auburn University, USA

Alison Connolly, University College Dublin, Ireland

Aqiel Dalvie, University of Cape Town, South Africa

Anneclaire De Roos, Dornsife School of Public Health, Drexel University, USA

Marcelo Ferreira, Post-Graduate Program of Public Health, Federal University of Ceará Medical School, Brazil

Mary Beth Genter, College of Medicine, University of Cincinnati, USA

Ludovic Le Hégarat, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), France

Stefano Lorenzetti, Istituto Superiore di Sanità, Italy

Daniele Mandrioli, Cesare Maltoni Cancer Research Center, Ramazzini Institute, Italy

John McLaughlin, Dalla Lana School of Public Health, University of Toronto, Canada

Peter Møller, Section of Environmental Health, Department of Public Health, University of Copenhagen, Denmark

Cassiana C Montagner, University of Campinas, Brazil

Neil Pearce, London School of Hygiene and Tropical Medicine, UK


Anjoeka Pronk, Netherlands Organisation for Applied Scientific Research (TNO), Netherlands

Henrique CS Silveira, Molecular Oncology Research Center, Barretos Cancer Hospital, Brazil

Anatoly Soshilov, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, USA

Takeshi Toyoda, Division of Pathology, National Institute of Health Sciences, Japan

David H Volle, Université Clermont Auvergne and Institut national de la santé et de la recherche médicale (INSERM), France



None

Representatives of national and international health agencies

Alín Manuel Gherasim, Spanish Ministry of Health, Spain (withdrew)

Observers

Remi Bars, Regulatory Science Associates, UK¹

Alex Charlton, Syngenta, USA²

Monika Kemeny, BASF, Germany³

Nicolo R. Visconti, Bayer US, USA⁴

IARC Secretariat

Marie-Laure Aix, Genomic Epidemiology Branch

Lamia Benbrahim-Tallaa, *IARC Monographs Programme*

Aline de Conti, *IARC Monographs Programme*

Xiaobei Deng, *IARC Monographs Programme*

Rachmad Anres Dongoran, Epigenomics and Mechanisms Branch

Caterina Facchin, *IARC Monographs Programme*

Andrew Kunzmann, *IARC Monographs Programme*

Federica Madia, *IARC Monographs Programme*

Heidi Mattock, *IARC Monographs Programme*

Michael Olanipekun, Genomic Epidemiology Branch

Elisa Pasqual, *IARC Monographs Programme*

Mary Schubauer-Berigan, *IARC Monographs Programme* (Programme Head)

Eero Suonio, *IARC Monographs Programme*

Susana Viegas, *IARC Monographs Programme*

Roland Wedekind, *IARC Monographs Programme* (Responsible Officer)


NOTE REGARDING CONFLICTS OF INTERESTS: Each participant first received a preliminary invitation with the request to complete and sign the IARC/WHO Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial or non-financial interests (e.g. public statements and positions related to the subject of the meeting).

¹ Dr Bars reports being employed by Regulatory Science Ltd and receiving support for travel and accommodation from CropLife International, an international trade association of agrochemical companies.

² Dr Charlton reports being employed by (and receiving support for travel and accommodation from) Syngenta LLC, which is a chemical company manufacturing and selling products containing the agents reviewed at the present meeting.

³ Dr Kemeny reports being employed by (and receiving support for travel and accommodation from) BASF, which is a chemical company owning intellectual property on mixtures containing some of the agents reviewed at the present meeting.

⁴ Dr Visconti reports being employed by (and receiving support for travel and accommodation from) Bayer Crop sciences US LLC, which is a chemical company manufacturing and selling products containing the agents reviewed at the present meeting.



Official invitations were extended after careful assessment of any declared interests that might constitute a conflict of interest. Pertinent and significant conflicts are disclosed here. Information about other potential conflicts that are not disclosed may be sent to the Head of the *IARC Monographs* Programme at imo@iarc.who.int.

Participants identified as Invited Specialists did not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. The Declarations were be updated and reviewed again at the opening of the meeting.

Posted on 4 November